Patients with clinically active disease had decreased clinical measures of albumin (a decrease indicates reduced liver function) and increased non-alcoholic fatty liver disease (NAFLD) fibrosis scores (a non-invasive score that identifies liver fibrosis [25]) (Figure 3D), suggesting altered liver function. This evidence concerns the gene ALB and metabolic dysfunction-associated steatotic liver disease.